Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials.

Published on May 1, 2019in Acta Psychiatrica Scandinavica5.362
· DOI :10.1111/ACPS.13016
Ole Köhler-Forsberg11
Estimated H-index: 11
(Aarhus University Hospital),
Cecilie N. Lydholm2
Estimated H-index: 2
(Copenhagen University Hospital)
+ 3 AuthorsMichael E. Benros32
Estimated H-index: 32
(Lundbeck)
Sources
Abstract
BACKGROUND: No study has gathered evidence from all randomized clinical trials (RCTs) with anti-inflammatory drugs measuring antidepressant effects including a detailed assessment of side-effects and bias. METHODS: We performed a systematic review identifying RCTs published prior to January 1, 2018, studying antidepressant treatment effects and side-effects of pharmacological anti-inflammatory intervention in adults with major depressive disorder (MDD) or depressive symptoms. Outcomes were depression scores after treatment, remission, response, and side-effects. Pooled standard mean differences (SMD) and risk ratios (RR) including 95% confidence intervals (95%-CI) were calculated. RESULTS: We identified 36 RCTs, whereof 13 investigated NSAIDs (N = 4214), 9 cytokine inhibitors (N = 3345), seven statins (N = 1576), 3 minocycline (N = 151), 2 pioglitazone (N = 77), and 2 glucocorticoids (N = 59). Anti-inflammatory agents improved depressive symptoms compared to placebo as add-on in patients with MDD (SMD = -0.64; 95%-CI = -0.88, -0.40; I2  = 51%; N = 597) and as monotherapy (SMD = -0.41; 95%-CI = -0.60, -0.22; I2  = 93%, N = 8825). Anti-inflammatory add-on improved response (RR = 1.76; 95%-CI = 1.44-2.16; I2  = 16%; N = 341) and remission (RR = 2.14; 95%-CI = 1.03-4.48; I2  = 57%; N = 270). We found a trend toward an increased risk for infections, and all studies showed high risk of bias. CONCLUSION: Anti-inflammatory agents improved antidepressant treatment effects. Future RCTs need to include longer follow-up, identify optimal doses and subgroups of patients that can benefit from anti-inflammatory intervention.
📖 Papers frequently viewed together
446 Citations
245 Citations
2,813 Citations
References62
Newest
#1Andrea Cipriani (University of Oxford)H-Index: 67
#2Toshi A. Furukawa (Kyoto University)H-Index: 70
Last. John R. Geddes (University of Oxford)H-Index: 87
view all 18 authors...
Summary Background Major depressive disorder is one of the most common, burdensome, and costly psychiatric disorders worldwide in adults. Pharmacological and non-pharmacological treatments are available; however, because of inadequate resources, antidepressants are used more frequently than psychological interventions. Prescription of these agents should be informed by the best available evidence. Therefore, we aimed to update and expand our previous work to compare and rank antidepressants for ...
1,039 CitationsSource
#1Brian V. Broberg (UCPH: University of Copenhagen)H-Index: 14
#2Iris E. C. Sommer (UMCG: University Medical Center Groningen)H-Index: 76
Last. Ole Köhler-Forsberg (Copenhagen University Hospital)H-Index: 11
view all 6 authors...
Abstract Glucocorticoids can have psychosis as a potential side effect, but have also been suggested to yield protective effects due to anti-inflammatory properties. Nonetheless, knowledge is sparse on the association between glucocorticoid treatment and development of psychosis, which we aimed to study in this first large-scale longitudinal study. Among all individuals born in Denmark 1995–2003 ( n = 597,257), we compared individuals who had redeemed ≥1 prescription for glucocorticoids to an ac...
5 CitationsSource
#1Nils Kappelmann (University of Cambridge)H-Index: 5
#1Nils Kappelmann (University of Cambridge)H-Index: 3
Last. Golam M. Khandaker (University of Cambridge)H-Index: 20
view all 5 authors...
GMK is supported by a Clinical Lecturer Starter Grant from the Academy of Medical Sciences, UK (grant no. 80354) and a Gosling Fellowship from the Royal College of Psychiatrists, UK (2015). GMK also received funding support from the Wellcome Trust 094790/Z/10/Z). PBJ acknowledges grant sup port from the Wellcome Trust (095844/Z/11/Z & 088869/Z/09/Z) and NIHR (RP-PG-0606-1335, Cambridge Biomedical Research Centre and CLAHRC East of England). RD has received grants from the National Institute of N...
245 CitationsSource
#1Yu Sun (Johnson & Johnson)H-Index: 4
#2D. Wang (Johnson & Johnson)H-Index: 3
Last. Guang Chen (Johnson & Johnson)H-Index: 3
view all 12 authors...
Abstract Cytokines, including interleukin-6 (IL-6), modulate neuronal plasticity and stress coping. Depressive symptoms and major depressive disorder (MDD) have been associated with changes in cytokines and their signaling. The current study examined the effect of IL-6 monoclonal antibody administration on depressive symptoms in patients with rheumatoid arthritis (RA) or multicentric Castleman’s disease (MCD). The data were obtained from two phase 2, double-blind, placebo-controlled trials desig...
36 CitationsSource
#2Maurizio Fava (Harvard University)H-Index: 151
Last. Mark Hyman Rapaport (Emory University)H-Index: 67
view all 8 authors...
Background: Depression is a common comorbidity in psoriasis, and both conditions are associated with systemic inflammation. The efficacy of ixekizumab, a high-aff
39 CitationsSource
#1Nicolas ZdanowiczH-Index: 8
#2Christine ReynaertH-Index: 23
Last. Thomas DuboisH-Index: 3
view all 5 authors...
BACKGROUND: Antidepressant medication efficacy remains a major research challenge. Here, we explored four questions: whether noradrenergic antidepressants are more effective than serotonergic antidepressants; whether the addition of 100 mg acetylsalicylic acid (ASA) changes antidepressant efficacy; whether the long-term efficacy differs depending on the antidepressant and the addition of ASA; and whether serum levels of brain-derived neurotrophic factor (BDNF) are clinically informative. SUBJECT...
4 Citations
#1Maryam Alamdarsaravi (Tehran University of Medical Sciences)H-Index: 1
#2Alireza Ghajar (Tehran University of Medical Sciences)H-Index: 18
Last. Shahin Akhondzadeh (Tehran University of Medical Sciences)H-Index: 64
view all 10 authors...
Abstract Cancer-related inflammation is an essential process in malignancies. Celecoxib, a nonsteroidal anti-inflammatory drug that acts via the selective inhibition of cyclooxygenase (COX)-2, has shown favorable effects in several psychiatric disorders. The present study aimed to assess the safety and efficacy of celecoxib single therapy on depressive symptoms of patients with colorectal cancer who underwent chemotherapy. The study was conducted as a 6-week, parallel-group, randomized, double-b...
19 CitationsSource
#1Muhammad Ishrat Husain (Camden and Islington NHS Foundation Trust)H-Index: 11
#2Imran B ChaudhryH-Index: 20
Last. Allan H. YoungH-Index: 106
view all 10 authors...
Background:Evidence suggests that anti-inflammatory medication may be effective in the treatment of depressive symptoms. In this study, we aimed to investigate whether minocycline added to treatment as usual (TAU) for 3 months in patients with treatment-resistant depression will lead to an improvement in depressive symptoms.Methods:Multi-site, 12-week, double-blind, placebo-controlled, pilot trial of minocycline added to TAU for patients suffering from DSM-5 major depressive disorder, whose curr...
62 CitationsSource
#1Dennis Chan (University of Cambridge)H-Index: 24
#2Sophie Binks (Brighton and Sussex University Hospitals NHS Trust)H-Index: 1
Last. Jeremy Chataway (UCL Institute of Neurology)H-Index: 36
view all 9 authors...
Summary Background In the 24-month MS-STAT phase 2 trial, we showed that high-dose simvastatin significantly reduced the annualised rate of whole brain atrophy in patients with secondary progressive multiple sclerosis (SPMS). We now describe the results of the MS-STAT cognitive substudy, in which we investigated the treatment effect on cognitive, neuropsychiatric, and health-related quality-of-life (HRQoL) outcome measures. Methods We did a secondary analysis of MS-STAT, a 24-month, double-blind...
60 CitationsSource
#1Olivia M Dean (Deakin University)H-Index: 42
#2Buranee Kanchanatawan (Chula: Chulalongkorn University)H-Index: 19
Last. Michael BerkH-Index: 131
view all 15 authors...
Objective:Conventional antidepressant treatments result in symptom remission in 30% of those treated for major depressive disorder, raising the need for effective adjunctive therapies. Inflammation has an established role in the pathophysiology of major depressive disorder, and minocycline has been shown to modify the immune-inflammatory processes and also reduce oxidative stress and promote neuronal growth. This double-blind, randomised, placebo-controlled trial examined adjunctive minocycline ...
48 CitationsSource
Cited By94
Newest
#1Xi Chen (SJTU: Shanghai Jiao Tong University)
#2Yifan Chen (Tufts University)
Last. Donghong Cui (SJTU: Shanghai Jiao Tong University)H-Index: 8
view all 4 authors...
Inflammation is involved in the pathogenesis of psychiatric disorders. Many previous studies have defined the important roles of inflammatory factors in the pathogenesis, diagnosis, and treatment outcomes of psychiatric disorders. Macrophage migration inhibitory factor (MIF), a pro-inflammatory factor, has been gradually recognized to be involved in the development of neurological diseases in recent years. Our current review focuses on discussing the potential beneficial and detrimental roles of...
Source
#1Monojit Debnath (National Institute of Mental Health and Neurosciences)H-Index: 16
#2Michael Berk (Florey Institute of Neuroscience and Mental Health)H-Index: 131
Last. Michael Maes (Chula: Chulalongkorn University)H-Index: 89
view all 3 authors...
Major depressive disorder (MDD) is a common, severe and disabling neuropsychiatric disorder with a heterogenous aetiology. Among the most widely recognized etiological models, immunopathogenesis is a predominant one. Numerous studies have demonstrated aberrant levels of inflammatory markers in the peripheral blood, cerebrospinal fluid (CSF) and brain of patients with MDD. Multiple studies and meta-analyses have reported increased peripheral levels of acute phase proteins, and pro-inflammatory cy...
Source
#1Éimear M Foley (University of Cambridge)H-Index: 1
#2Joel T. Parkinson (Glas.: University of Glasgow)H-Index: 1
Last. Gulam KhandakerH-Index: 34
view all 4 authors...
Abstract null null Whether depressed patients with evidence of inflammation are more appropriate candidates for immunotherapies is being tested in several clinical trials, which are selecting patients based on elevated C-reactive protein (CRP) and inflammation-related symptoms. However, studies of the clinical and phenotypic profile of depressed patients with elevated CRP are relatively scarce. We have investigated detailed clinical characteristics of 84 depressed patients, grouped as those with...
Source
#1Robyn J. McQuaid (U of O: University of Ottawa)H-Index: 17
Abstract null null Depression is a multifaceted disorder characterized by heterogeneous symptom profiles and high rates of comorbidity with other commonly occurring mental illnesses. Considering the burden of mental health disorders and the lack of efficacy of available treatments, there is a need for biomarkers to predict tailored or personalized treatments. However, identifying reliable biomarkers for complex mental illnesses, such as depression, anxiety and PTSD, has been challenging, likely ...
Source
#1Sonja Orlovska-Waast (Copenhagen University Hospital)H-Index: 2
#2Liselotte Petersen (AU: Aarhus University)H-Index: 31
Last. Michael E. Benros (Copenhagen University Hospital)H-Index: 32
view all 0 authors...
BACKGROUND Cerebrospinal fluid (CSF) immune alterations have been associated with mental disorders, neurological disease, and CNS infections; however, comprehensive large-scale longitudinal CSF studies are lacking. METHODS By using the Clinical Laboratory Information System (LABKA) Research Database in the Central Denmark Region (1994-2012), we included 15,030 individuals tested for CSF WBC, CSF/serum albumin ratio, IgG index, total protein, albumin, or IgG with follow-up for the risk of mental ...
Source
#1Bernhard T. BauneH-Index: 95
#2Emma Sampson (University of Adelaide)H-Index: 2
Last. Célia Fourrier (University of Adelaide)H-Index: 6
view all 8 authors...
Given the role of low-grade inflammation in the pathophysiology of major depressive disorder (MDD), anti-inflammatory strategies may improve treatment outcomes in some patients. However, it is controversial whether they can be used as adjunctive treatments and whether pre-treatment levels of inflammation can predict treatment outcomes. This study was conducted to measure the efficacy of anti-inflammatory augmentation of antidepressant treatment in MDD patients; and to investigate whether treatme...
Source
#1Xiaoyue Zhao (Peking Union Medical College)H-Index: 2
#2Dewen Kong (Peking Union Medical College)H-Index: 1
Last. Guanhua Du (Peking Union Medical College)H-Index: 61
view all 7 authors...
BACKGROUND Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder in the world. In addition to motor symptoms, a variety of non-motor symptoms seriously affect the life quality of PD patients. Baicalein, a flavonoid extracted from the herb Scutellaria baicalensis Georgi, exhibits anti-PD activity through alleviation of its motor symptoms. However, its effects on non-motor symptoms were barely reported. This study aimed to investigate the therapeutic effects of baicalein...
Source
#1Necati Serkut Bulut (Marmara University)H-Index: 1
#2Neşe Yorguner (Marmara University)H-Index: 2
Last. Gresa Carkaxhiu Bulut (Maltepe University)H-Index: 3
view all 3 authors...
BACKGROUND As non-specific markers of immune dysregulation, neutrophil-lymphocyte and platelet-lymphocyte ratios (NLR and PLR) have been consistently shown to be increased in major neuropsychiatric disorders. Although this increase seems to be trans-diagnostic, the extent to which its magnitude differs between disorders remains largely unclear. AIM The aim of this study was to directly compare the severity of inflammation (as reflected by NLR and PLR) between schizophrenia (Sch), bipolar mania (...
Source
#1Xiao-Le Wang (Beijing University of Chinese Medicine)H-Index: 2
#2Si-Tong Feng (Beijing University of Chinese Medicine)H-Index: 4
Last. Yi Zhang (Beijing University of Chinese Medicine)H-Index: 10
view all 6 authors...
Abstract null null Background null Depression, as a prevalent and debilitating psychiatric disease, severely decreases the life quality of individuals and brings heavy burdens to the whole society. Currently, some antidepressants are applied in the treatment of severe depressive symptoms, while there are still some undesirable drawbacks. Paeoniflorin is a monoterpenoid glycoside that was firstly extracted from Paeonia lactiflora Pall, a traditional Chinese herb that is widely used in the Chinese...
Source
#1Shinji Sakamoto (JHUSOM: Johns Hopkins University School of Medicine)
#2Xiaolei Zhu (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 7
Last. Atsushi Kamiya (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 31
view all 7 authors...
Although there are a number of clinically effective treatments for depression, many patients exhibit treatment-resistance. Recent clinical and preclinical studies reveal that peripheral and brain immune changes and inflammation are involved in the pathophysiology of depression. This "Inflamed Brain" research provides critical clues for understanding of disease pathophysiology and many candidate molecules that are potentially useful for identifying novel drug targets for the treatment of depressi...
Source